Avexa chairman Nathan Drona is defending its proposed merger with Progen, saying the deal will help it gain a more lucrative pact for its HIV drug ACT. Some Progen investors, though, say the merger doesn't reflect the true value of the company and its $60 million in cash. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments